Anavex Life Sciences (AVXL) Stock Forecast, Price Target & Predictions
AVXL Stock Forecast
Anavex Life Sciences stock forecast is as follows: an average price target of $11.00 (represents a 101.47% upside from AVXL’s last price of $5.46) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
AVXL Price Target
The average price target for Anavex Life Sciences (AVXL) is $11.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $11.00 to $11.00. This represents a potential 101.47% upside from AVXL's last price of $5.46.
AVXL Analyst Ratings
According to 6 Wall Street analysts, Anavex Life Sciences's rating consensus is 'Buy'. The analyst rating breakdown for AVXL stock is 0 'Strong Buy' (0.00%), 4 'Buy' (66.67%), 2 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Anavex Life Sciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 06, 2022 | - | Cantor Fitzgerald | $11.00 | $8.54 | 28.85% | 101.47% |
The latest Anavex Life Sciences stock forecast, released on Dec 06, 2022 by Cantor Fitzgerald company, set a price target of $11.00, which represents a 28.85% increase from the stock price at the time of the forecast ($8.54), and a 101.47% increase from AVXL last price ($5.46).
Anavex Life Sciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $5.46 | $5.46 | $5.46 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Anavex Life Sciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Anavex Life Sciences's last price of $5.46. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 22, 2024 | EF Hutton | - | Buy | Initialise |
| Jan 03, 2023 | Piper Sandler | Overweight | Overweight | Hold |
| Jan 03, 2023 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Jan 03, 2023 | Needham | Buy | Buy | Hold |
| Jan 03, 2023 | Keefe, Bruyette & Woods | Outperform | Outperform | Hold |
| Dec 06, 2022 | Cantor Fitzgerald | - | Neutral | Downgrade |
Anavex Life Sciences's last stock rating was published by EF Hutton on Jul 22, 2024. The company Initialise its AVXL rating from "null" to "Buy".
Anavex Life Sciences Financial Forecast
Anavex Life Sciences Revenue Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Avg Forecast | $111.56M | $71.73M | $45.53M | $45.92M | - | - | - | - |
| High Forecast | $111.56M | $71.73M | $45.53M | $45.92M | - | - | - | - |
| Low Forecast | $111.56M | $71.73M | $45.53M | $45.92M | - | - | - | - |
| # Analysts | - | - | - | - | - | - | 2 | 1 |
| Surprise % | - | - | - | - | - | - | - | - |
Anavex Life Sciences's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. AVXL's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Anavex Life Sciences EBITDA Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | 2 | 1 |
| EBITDA | - | - | - | - | - | - | - | $-8.54M |
| Avg Forecast | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - |
undefined analysts predict AVXL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Anavex Life Sciences's previous annual EBITDA (undefined) of $NaN.
Anavex Life Sciences Net Income Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | 2 | 1 |
| Net Income | - | - | - | - | - | - | - | $-8.45M |
| Avg Forecast | $-15.22M | $-19.44M | $-16.91M | $-16.06M | $-13.24M | $-13.53M | $-9.07M | $-11.90M |
| High Forecast | $-15.22M | $-19.44M | $-16.91M | $-16.06M | $-13.24M | $-13.53M | $-9.07M | $-11.90M |
| Low Forecast | $-15.22M | $-19.44M | $-16.91M | $-16.06M | $-13.24M | $-13.53M | $-9.07M | $-11.90M |
| Surprise % | - | - | - | - | - | - | - | 0.71% |
Anavex Life Sciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AVXL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Anavex Life Sciences SG&A Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | 2 | 1 |
| SG&A | - | - | - | - | - | - | - | $2.61M |
| Avg Forecast | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - |
Anavex Life Sciences's average Quarter SG&A projection for Mar 24 is -, based on 2 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to AVXL last annual SG&A of $2.61M (Dec 23).
Anavex Life Sciences EPS Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | 2 | 1 |
| EPS | - | - | - | - | - | - | - | $0.11 |
| Avg Forecast | $-0.18 | $-0.23 | $-0.20 | $-0.19 | $-0.16 | $-0.16 | $-0.11 | $-0.14 |
| High Forecast | $-0.18 | $-0.23 | $-0.20 | $-0.19 | $-0.16 | $-0.16 | $-0.11 | $-0.14 |
| Low Forecast | $-0.18 | $-0.23 | $-0.20 | $-0.19 | $-0.16 | $-0.16 | $-0.11 | $-0.14 |
| Surprise % | - | - | - | - | - | - | - | -0.76% |
According to 2 Wall Street analysts, Anavex Life Sciences's projected average Quarter EPS for Mar 24 is $-0.11, with a low estimate of $-0.11 and a high estimate of $-0.11. This represents a -200.00% decrease compared to AVXL previous annual EPS of $0.11 (Dec 23).
Anavex Life Sciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BTAI | BioXcel Therapeutics | $0.63 | $13.00 | 1963.49% | Buy |
| KOD | Kodiak Sciences | $2.68 | $32.80 | 1123.88% | Buy |
| NVAX | Novavax | $12.93 | $74.67 | 477.49% | Buy |
| INMB | INmune Bio | $5.55 | $22.00 | 296.40% | Buy |
| ANVS | Annovis Bio | $8.74 | $23.50 | 168.88% | Buy |
| IOVA | Iovance Biotherapeutics | $10.42 | $21.57 | 107.01% | Buy |
| AVXL | Anavex Life Sciences | $5.46 | $11.00 | 101.47% | Buy |
| VKTX | Viking Therapeutics | $62.94 | $100.50 | 59.68% | Buy |
| MDGL | Madrigal Pharmaceuticals | $233.36 | $315.75 | 35.31% | Buy |
| AXSM | Axsome Therapeutics | $90.94 | $117.83 | 29.57% | Buy |
| TGTX | TG Therapeutics | $25.08 | $26.40 | 5.26% | Buy |
| EXEL | Exelixis | $27.60 | $28.30 | 2.54% | Buy |
AVXL Forecast FAQ
Is Anavex Life Sciences a good buy?
Yes, according to 6 Wall Street analysts, Anavex Life Sciences (AVXL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 66.67% of AVXL's total ratings.
What is AVXL's price target?
Anavex Life Sciences (AVXL) average price target is $11 with a range of $11 to $11, implying a 101.47% from its last price of $5.46. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Anavex Life Sciences stock go up soon?
According to Wall Street analysts' prediction for AVXL stock, the company can go up by 101.47% (from the last price of $5.46 to the average price target of $11), up by 101.47% based on the highest stock price target, and up by 101.47% based on the lowest stock price target.
Can Anavex Life Sciences stock reach $8?
AVXL's average twelve months analyst stock price target of $11 supports the claim that Anavex Life Sciences can reach $8 in the near future.
What are Anavex Life Sciences's analysts' financial forecasts?
Anavex Life Sciences's analysts financial forecasts for the fiscal year (Sep 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-47.742M (high $-47.742M, low $-47.742M), average SG&A $0 (high $0, low $0), and average EPS is $-0.572 (high $-0.572, low $-0.572). AVXL's analysts financial forecasts for the fiscal year (Sep 2025) are as follows: average revenue is $274.74M (high $274.74M, low $274.74M), average EBITDA is $0 (high $0, low $0), average net income is $-67.628M (high $-67.628M, low $-67.628M), average SG&A $0 (high $0, low $0), and average EPS is $-0.8 (high $-0.8, low $-0.8).